Research graph
References from Repurposing ritonavir to induce proteasomal degradation of IE1 for inhibition of human cytomegalovirus replication. Local targets link to admitted publications; unresolved targets remain external evidence.
A systematic literature review of the global seroprevalence of cytomegalovirus: Possible implications for treatment, screening, and vaccine development
10.1186/s12889-022-13971-7 · 2022 · External reference
Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy
10.1186/s12879-019-4643-6 · 2019 · External reference
Cytomegalovirus (CMV) pneumonitis: Cell tropism, inflammation, and immunity
10.3390/ijms20163865 · 2019 · External reference
Human cytomegalovirus infection and neurocognitive and neuropsychiatric health
10.3390/pathogens13050417 · 2024 · External reference
The “silent” global burden of congenital cytomegalovirus
10.1128/cmr.00062-12 · 2013 · External reference
Cytomegalovirus infection in transplant recipients
10.6061/clinics/2015(07)09 · 2015 · External reference
Analysis of novel drug-resistant human cytomegalovirus DNA polymerase mutations reveals the role of a DNA-binding loop in phosphonoformic acid resistance
10.3389/fmicb.2022.771978 · 2022 · External reference
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation
10.1056/nejmoa1309533 · 2014 · External reference
The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation
10.1097/tp.0000000000005374 · 2025 · External reference
Challenges and advances in the management of HCMV infections
10.1684/vir.2024.1063 · 2024 · External reference
An overview of letermovir: A cytomegalovirus prophylactic option
10.1080/14656566.2019.1637418 · 2019 · External reference
Human cytomegalovirus (HCMV) immediate-early enhancer/promoter specificity during embryogenesis defines target tissues of congenital HCMV infection
10.1128/jvi.69.4.2194-2207.1995 · 1995 · External reference
The human cytomegalovirus major immediate-early proteins as antagonists of intrinsic and innate antiviral host responses
10.3390/v1030760 · 2009 · External reference
The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells
10.1128/jvi.71.6.4599-4613.1997 · 1997 · External reference
Human cytomegalovirus IE2 both activates and represses initiation and modulates elongation in a context-dependent manner
2022 · External reference
Human cytomegalovirus IE2 drives transcription initiation from a select subset of late infection viral promoters by host RNA polymerase II
2020 · External reference
The human cytomegalovirus IE2 and UL112-113 proteins accumulate in viral DNA replication compartments that initiate from the periphery of promyelocytic leukemia protein-associated nuclear bodies (PODs or ND10)
10.1128/jvi.73.12.10458-10471.1999 · 1999 · External reference
Who’s driving? Human cytomegalovirus, interferon, and NFκB signaling
10.3390/v10090447 · 2018 · External reference
Human cytomegalovirus immediate-early 1 protein rewires upstream STAT3 to downstream STAT1 signaling switching an IL6-type to an IFNγ-like response
10.1371/journal.ppat.1005748 · 2016 · External reference
Identification of cellular proteins that interact with human cytomegalovirus immediate-early protein 1 by protein array assay
10.3390/v6010089 · 2013 · External reference
Role of human cytomegalovirus immediate-early proteins in cell growth control
10.1128/jvi.74.17.8028-8037.2000 · 2000 · External reference
Human cytomegalovirus mediates cell cycle progression through G(1) into early S phase in terminally differentiated cells
10.1099/0022-1317-81-6-1553 · 2000 · External reference
Bright and early: Inhibiting human cytomegalovirus by targeting major immediate-early gene expression or protein function
10.3390/v12010110 · 2020 · External reference
RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions
10.1128/jvi.06338-11 · 2012 · External reference
Cytomegalovirus immediate-early 1 proteins form a structurally distinct protein class with adaptations determining cross-species barriers
10.1371/journal.ppat.1009863 · 2021 · External reference
RCSB Protein Data Bank (RCSB.org): Delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning
10.1093/nar/gkac1077 · 2023 · External reference
ZINC--a free database of commercially available compounds for virtual screening
10.1021/ci049714+ · 2005 · External reference
Beware of docking!
10.1016/j.tips.2014.12.001 · 2015 · External reference
A simple method of estimating fifty per cent endpoints
10.1093/oxfordjournals.aje.a118408 · 1938 · External reference
Virus isolation and quantitation.
10.1016/b978-012465330-6/50003-8 · 1996 · External reference
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
10.1056/nejm199512073332204 · 1995 · External reference
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
10.1016/j.biopha.2023.114367 · 2023 · External reference
Ritonavir-boosted protease inhibitor based therapy: A new strategy in chronic hepatitis C therapy
10.1586/17474124.2015.1032938 · 2015 · External reference
Lopinavir-ritonavir in SARS-CoV-2 infection and drug-drug interactions with cardioactive medications
10.1007/s10557-020-07070-1 · 2021 · External reference
The human CMV IE1 protein: An offender of PML nuclear bodies
10.1007/978-3-319-53168-7_4 · 2017 · External reference
The human cytomegalovirus IE1 protein antagonizes PML nuclear body-mediated intrinsic immunity via the inhibition of PML de novo SUMOylation
2017 · External reference
Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO
10.1128/jvi.00833-08 · 2008 · External reference
Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2
10.1128/jvi.01164-09 · 2009 · External reference
Crystal structure of cytomegalovirus IE1 protein reveals targeting of TRIM family member PML via coiled-coil interactions
10.1371/journal.ppat.1004512 · 2014 · External reference
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
10.1186/s13045-020-00885-3 · 2020 · External reference
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
10.1016/j.drudis.2025.104376 · 2025 · External reference
Targeted protein degradation as an antiviral approach
10.1016/j.antiviral.2022.105480 · 2023 · External reference
Antiviral strategies based on targeted protein degradation: An overview of the literature and future outlook
10.1016/j.ejmech.2025.118208 · 2026 · External reference
Targeted degrader technologies as prospective SARS-CoV-2 therapies
10.1016/j.drudis.2023.103847 · 2024 · External reference
Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
10.1038/nm0898-953 · 1998 · External reference
Long-term outcomes of cytomegalovirus retinitis in the era of modern antiretroviral therapy: Results from a United States cohort
10.1016/j.ophtha.2015.02.033 · 2015 · External reference
DRHIN: An integrated and interactive web server for drug repositioning
10.1021/acs.jcim.6c00311 · 2026 · External reference
Atom size electron vortex beams with selectable orbital angular momentum
10.1038/s41598-017-01077-9 · 2017 · External reference
SurfDock is a surface-informed diffusion generative model for reliable and accurate protein-ligand complex prediction
10.1038/s41592-024-02516-y · 2025 · External reference
LiTENexus: An end-to-end virtual drug discovery system based on quantum chemical grounding
2026 · External reference
